

Title (en)
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS

Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON IMMUNKRANKHEITEN

Title (fr)
COMPOSITIONS PHARMACEUTIQUES POUR THERAPIE A BUT IMMUNITAIRE

Publication
EP 0929568 A2 19990721 (EN)

Application
EP 97939105 A 19970910

Priority
• IB 9701086 W 19970910
• US 2518096 P 19960911

Abstract (en)
[origin: WO9810787A2] Herein is described a specific amino acid sequence which exhibits specific Ion (bridge) pair arrays enclosed on at least one side by non polar hydrophobic transmembrane segments, as a mechanism used by many infectious agents and a number of cytokine inhibitory factors, such as Interleukin 10 and Prolactin Inhibitory factor and alfa-fetoprotein, to not only undermine the hosts immune defences but to also allow for the infection of target lymphoid tissue. It has been demonstrated that certain vaccines, when inoculated into a host, produced a range of neutralising antibodies but failed to prevent infection when that host is later challenged with live infectious organism. This present patent illustrates that when such vaccine inoculation is coupled with passive immunisation with mono or polyclonal antibodies to these specific amino acid sequences as specified herein that the host is then capable of overcoming the infectious challenge. Herein is described the therapeutic use of mono or polyclonal antibodies to these said specific sequences as a treatment for Acquired Immune Deficiency Syndrome (AIDS) and other disease states that persist due to the presence of a cytokine inhibitory factor of viral, fungal, bacterial or host origin such as Chronic Fatigue Syndrome where Interleukin 10 mimic molecules are responsible for a multitude of disease symptoms identified as indicative of Myalgic Encephalitis. Herein is described the therapeutic use of mono or polyclonal antibodies to these specific amino acid sequences as a combination therapy with vaccines and anti-viral agents to prevent side effects from certain immune modulation and anti-viral agents (e.g. DHEA and IL-12) which cause enhanced production of Interleukin 10 or AFP mimic molecules during therapy. Also herein is described the therapeutic use of these specific sequences either isolated from the organism source or produced by direct synthesis or recombinant protein synthesis. These peptides when administered to a patient suffering from an auto-immune disease, such as Multiple Sclerosis (MS), Lupus (systemic Lupus erythematoses) or diabetes or rheumatoid arthritis as limited examples or to transplant organ recipients, will allow the patient's immune state to be shifted to a Th2 antibody dependent immune response and curtail the Th1 (T cell dependent) immune attack which is evident in such immune malfunctions as MS and graft versus host disease. Certain dermatological conditions which are today treated by the use of corticosteroid creams and ointment may also be successfully treated by replacing the corticosteroid with these mimic immunosuppressive AFP/Interleukin 10 sequences outlined in this patent.

IPC 1-7
C07K 4/00; C07K 5/08; C07K 7/08; C07K 14/54; C07K 16/24; A61K 38/20; A61K 39/385; A61K 39/395

IPC 8 full level
C12N 15/02 (2006.01); **A61K 38/00** (2006.01); **A61K 38/06** (2006.01); **A61K 38/20** (2006.01); **A61K 39/395** (2006.01); **A61P 17/00** (2006.01); **A61P 25/00** (2006.01); **A61P 31/04** (2006.01); **A61P 33/06** (2006.01); **A61P 37/04** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C07K 5/08** (2006.01); **C07K 5/10** (2006.01); **C07K 7/06** (2006.01); **C07K 7/08** (2006.01); **C07K 14/155** (2006.01); **C07K 14/16** (2006.01); **C07K 14/54** (2006.01); **C07K 16/10** (2006.01); **C07K 16/18** (2006.01); **C07K 16/24** (2006.01); **C07K 16/44** (2006.01); **C12P 21/08** (2006.01); **A61K 39/00** (2006.01)

CPC (source: EP SE US)
A61K 38/06 (2013.01 - EP); **A61K 38/08** (2013.01 - SE); **A61K 38/2026** (2013.01 - EP SE); **A61K 38/2066** (2013.01 - EP SE); **A61K 39/385** (2013.01 - SE); **A61K 39/395** (2013.01 - SE); **A61P 17/00** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **A61P 33/06** (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07K 4/00** (2013.01 - SE); **C07K 5/08** (2013.01 - SE); **C07K 7/08** (2013.01 - SE); **C07K 14/005** (2013.01 - EP SE); **C07K 14/4715** (2013.01 - SE); **C07K 14/5428** (2013.01 - SE); **C07K 14/5434** (2013.01 - EP SE); **C07K 16/1063** (2013.01 - EP SE); **C07K 16/18** (2013.01 - EP); **C07K 16/244** (2013.01 - EP SE); **C07K 16/247** (2013.01 - EP SE); **G01N 33/56988** (2013.01 - SE); **A61K 39/00** (2013.01 - EP SE US); **C12N 2740/10011** (2013.01 - SE); **C12N 2740/15022** (2013.01 - EP); **C12N 2740/16111** (2013.01 - SE); **C12N 2740/16122** (2013.01 - EP); **Y02A 50/30** (2018.01 - EP)

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9810787 A2 19980319; WO 9810787 A3 19980730; AU 4132097 A 19980402; AU 6887096 A 19980402; CA 2265885 A1 19980319; CN 1230195 A 19990929; EP 0929568 A2 19990721; IL 128806 A0 20000131; JP 2001503613 A 20010321; NZ 335039 A 20010427; SE 9900812 D0 19990308; SE 9900812 L 19990308; WO 9810792 A1 19980319

DOCDB simple family (application)
IB 9701086 W 19970910; AU 4132097 A 19970910; AU 6887096 A 19960913; CA 2265885 A 19970910; CN 97197816 A 19970910; EP 97939105 A 19970910; IB 9600945 W 19960913; IL 12880697 A 19970910; JP 51343598 A 19970910; NZ 33503997 A 19970910; SE 9900812 A 19990308